## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-postherpetic`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-postherpetic/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-postherpetic/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-postherpetic/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-postherpetic/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-postherpetic/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-postherpetic/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-postherpetic` v2 · content_hash `569ce10b6bf6f777…` · thread_head genesis · 24 DIVs
- **thesis (c1):** Postherpetic neuralgia results from varicella-zoster virus damage to sensory nerve fibers, leading to persistent abnormal pain signaling.
  - c3 [human/active] No human trials have tested SS-31 in postherpetic neuralgia.
  - c5 [human/active] A 2018 randomized trial in 36 adults with primary mitochondrial myopathy showed SS-31 improved exercise performance after 5 days (human).
  - c4 [preclinical/active] In a 2026 mouse SCI model, SS-31 preserved mitochondrial function, reduced lesion size, and improved recovery (preclinical).
  - c2 [mechanistic/active] Mitochondrial dysfunction contributes to energy failure and oxidative stress in damaged neurons after nerve injury.
  - c6 [anecdotal/active] Anecdotal forum reports describe SS-31 use in trigeminal neuralgia and small-fiber neuropathy with subjective symptom changes.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-postherpetic/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-postherpetic/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-postherpetic`
- **title:** SS-31 (Elamipretide) and Postherpetic Neuralgia: Mitochondrial Repair in Damaged Nerves
- **url:** https://miscsubjects.com/a/ss-31-postherpetic
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:07.404Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Postherpetic neuralgia develops after shingles (herpes zoster) when the varicella-zoster virus damages sensory nerve fibers. The virus reactivates in nerve cells, causing inflammation and direct injury to axons and myelin sheaths. Damaged nerves then fire abnormal pain signals even after the rash clears. This creates burning, stabbing, or electric sensations that last months or years in the affected skin area.

Mitochondria inside neurons supply the energy needed for nerve repair and normal signaling. When mitochondria malfunction under oxidative stress, ATP drops, reactive oxygen species rise, and cell death pathways activate. In nerve injury models, this mitochondrial layer sits beneath the visible nerve damage and persistent pain signaling.

The core issue is degeneration outrunning repair: viral damage plus ongoing mitochondrial stress keeps nerves from returning to normal function. Standard treatments often focus on symptom suppression through nerve signal blockers rather than addressing energy production inside the cells.

## Why SS-31 (Elamipretide) might help you

SS-31 targets the inner mitochondrial membrane and binds cardiolipin. If mitochondrial dysfunction contributes to your ongoing nerve pain after shingles, this binding can stabilize the membrane, reduce electron leak, and preserve ATP production.

1. If oxidative stress in damaged sensory neurons is part of your problem, SS-31 is discussed because it scavenges reactive oxygen species at the source inside mitochondria.
2. If low energy in nerve cells limits natural repair processes, SS-31 is discussed because it supports electron transport chain efficiency without affecting healthy mitochondria.
3. If that mitochondrial layer sits under your persistent pain signals, SS-31 is discussed because it targets tissue-level repair pathways rather than masking pain at the receptor level.

## How these fit together

Single-compound focus — SS-31 maps directly to the mitochondrial degeneration layer. No sibling peptides are in scope, so the discussion stays on how improved mitochondrial bioenergetics could support neuronal integrity and reduce secondary inflammation in post-viral nerve damage.

## What the evidence actually shows

No human clinical trials have tested SS-31 in postherpetic neuralgia or any form of shingles-related nerve pain (preclinical tier for this specific condition).

In a 2026 mouse spinal cord injury study, SS-31 preserved mitochondrial homeostasis, reduced lesion burden, protected neurons, and improved functional recovery at 28 days post-injury (preclinical). In a 2023 mouse headache model induced by inflammatory soup, SS-31 reduced pain behaviors and restored mitochondrial function via Sirt3/Pgc-1α feedback (preclinical). In a 2019 mouse study using lipopolysaccharide to model neuroinflammation, SS-31 protected hippocampal mitochondria, maintained membrane potential and ATP, and prevented memory deficits (preclinical).

Human data exist only for primary mitochondrial myopathy. A 2018 randomized dose-escalation trial in 36 adults with genetically confirmed PMM found that 5 days of intravenous SS-31 improved exercise performance on the 6-minute walk test without safety signals (human). A later 2023 trial in the same population confirmed similar respiratory improvements in muscle biopsy studies (human). These trials did not measure neuropathic pain outcomes.

Evidence inventory: 0 human trials in postherpetic neuralgia; 3+ preclinical nerve-injury or neuroinflammation models in rodents; 2 human trials in primary mitochondrial myopathy; anecdotal reports on forums for related neuralgias (see Reddit section).

## What scientists say

Researchers describe SS-31 as a mitochondria-targeted tetrapeptide that selectively accumulates at cardiolipin and stabilizes respiratory chain function under stress. Reviews note consistent benefits in animal models of oxidative damage and neurodegeneration, yet emphasize the absence of direct data in viral or postherpetic neuropathy (mechanistic tier). They stress that effects appear only when mitochondrial dysfunction is present.

## What people say on Reddit

Anecdotal reports mention SS-31 in contexts of trigeminal neuralgia and small-fiber neuropathy. One user with trigeminal neuralgia tried SS-31 alongside vitamin D for cellular repair. Another user with small-fiber neuropathy reported that adding SS-31 (5 mg daily) improved tolerance to stressors and reduced twitching or tingling after alcohol intake, describing mitochondria as a suspected root cause. These remain individual experiences without controlled measurement or diagnosis of postherpetic neuralgia (anecdotal tier).

## What people say on X

No relevant posts found discussing SS-31 in relation to postherpetic neuralgia, PHN, or shingles nerve pain.

## What we do not know

Whether SS-31 reaches damaged sensory ganglia or peripheral nerves in sufficient concentration after shingles remains untested. No data exist on duration of treatment needed, interaction with the varicella-zoster virus itself, or long-term effects on pain scores in this population. Human evidence stops at primary mitochondrial diseases; extrapolation to post-viral nerve injury stays speculative.

## Safety and limits

In the human PMM trials, short courses of intravenous SS-31 showed no major adverse events. Preclinical studies report good tolerability in rodents. Because no trials exist for postherpetic neuralgia, safety and efficacy in that setting cannot be assessed from current data. All discussion remains limited to published mechanistic and animal findings.

## Claims (6)

- **c3** [human w=0.8] No human trials have tested SS-31 in postherpetic neuralgia.
  - who_claims: grok/grok-4.3
- **c5** [human w=0.8] A 2018 randomized trial in 36 adults with primary mitochondrial myopathy showed SS-31 improved exercise performance after 5 days (human).
  - who_claims: grok/grok-4.3
  - sources: s16
- **c1** [human w=0.8] Postherpetic neuralgia results from varicella-zoster virus damage to sensory nerve fibers, leading to persistent abnormal pain signaling.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c4** [preclinical w=0.5] In a 2026 mouse SCI model, SS-31 preserved mitochondrial function, reduced lesion size, and improved recovery (preclinical).
  - who_claims: grok/grok-4.3
  - sources: s9
- **c2** [mechanistic w=0.3] Mitochondrial dysfunction contributes to energy failure and oxidative stress in damaged neurons after nerve injury.
  - who_claims: grok/grok-4.3
  - sources: s9
- **c6** [anecdotal w=0.3] Anecdotal forum reports describe SS-31 use in trigeminal neuralgia and small-fiber neuropathy with subjective symptom changes.
  - who_claims: grok/grok-4.3
  - sources: s23

## Voxel graph (6 atoms · 11 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-postherpetic/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `1c6a1489b96459c9`

### s1 · medical · ok
- title: Postherpetic Neuralgia: What It Is, Symptoms & Treatment
- url: https://my.clevelandclinic.org/health/diseases/12093-postherpetic-neuralgia
- summary: Cleveland Clinic overview of PHN causes and nerve damage mechanism.
- quote: PHN happens when shingles damages your nerve fibers. These damaged nerves send stronger pain signals to your brain than they should.
- claim_ids: c1
- hash: `7dd5c80ad5573813`

### s9 · pubmed · http_403
- title: Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury
- url: https://www.sciencedirect.com/science/article/abs/pii/S0197018626000628
- summary: 2026 mouse SCI study showing mitochondrial and functional benefits.
- quote: SS-31 remodels the chronic injury microenvironment and enhances neural plasticity... preserves mitochondrial homeostasis and bioenergetics under oxidative stress.
- claim_ids: c2, c4
- hash: `84cac4a67caf83cb`

### s16 · pubmed · ok
- title: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
- url: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
- summary: 2018 human PMM trial results.
- quote: Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.
- claim_ids: c5
- hash: `f16f6b52c3d22017`

### s23 · reddit · ok
- title: Remission w Vitamin D
- url: https://www.reddit.com/r/TrigeminalNeuralgia/comments/1sigyhc/remission_w_vitamin_d/
- summary: User mention of SS-31 in trigeminal neuralgia context.
- quote: Only other thing I have tried was SS31 to do some cellular repair.
- claim_ids: c6
- hash: `1c6a1489b96459c9`

## Provenance (2 model passes)
- chain valid: yes · head: `a034f1d00b1e5b4f`

- write · grok/grok-4.3 · 2026-06-29T23:48 · hash `ef51802b7d82`
- voxel_divide · owner · 2026-07-17T02:42 · hash `a034f1d00b1e`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-postherpetic/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-postherpetic/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-postherpetic","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-postherpetic|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-postherpetic|tier|assertion`
- **iMessage ask:** `ss-31-postherpetic|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-postherpetic`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-postherpetic/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-postherpetic/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*